Research Article
Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)
Table 1
Baseline patient characteristics according to HbA1c levels at 24 weeks.
| | HbA1c ≤ 7.0% at 24 weeks () | HbA1c > 7.0% at 24 weeks () | Total () | value |
| Gender, n (%) | Male | 695 (56.5) | 449 (52.4) | 1144 (54.8) | 0.0633a | Age (years) | Mean ± SD | 56.8 ± 11.0 | 57.3 ± 11.7 | 57.0 ± 11.3 | 0.2517b | Weight (kg) | N | 1092 | 778 | 1870 | | Mean ± SD | 67.5 ± 11.0 | 66.3 ± 10.9 | 67 ± 11.0 | 0.0215b | Baseline HbA1c, n (%) | <7.5% | 650 (52.9) | 118 (13.8) | 768 (36.8) | <0.0001a | ≥7.5% | 580 (47.2) | 739 (86.2) | 1319 (63.2) | | Elderly group, n (%) | <65 years | 926 (75.3) | 611 (71.3) | 1537 (73.7) | 0.0418b | ≥65 years | 304 (24.7) | 246 (28.7) | 550 (26.4) | | Treatment center type, n (%) | Hospital | 600 (48.8) | 283 (33.0) | 883 (42.3) | <0.0001b | Clinic | 630 (51.2) | 574 (67.0) | 1204 (57.7) | | Concurrent disease, n (%) | Yes | 700 (56.9) | 449 (52.4) | 1149 (55.1) | 0.0412b | No | 530 (43.1) | 408 (47.6) | 938 (44.9) | | Medical history, n (%) | Yes | 153 (12.4) | 83 (9.7) | 236 (11.3) | 0.0296b | No | 1036 (84.2) | 756 (88.21) | 1792 (85.9) | | Concomitant medications (except for diabetes medications), n (%) | | | | | Yes | 733 (59.6) | 448 (52.3) | 1181 (56.6) | 0.0009b | No | 497 (40.4) | 409 (47.7) | 906 (43.4) | | Duration of T2DM (years) | n | 1067 | 785 | 1852 | | Mean ± SD | 5.1 ± 5.3 | 7.7 ± 6.0 | 6.2 ± 5.8 | <0.0001a | Drug combination type, n (%) | Vildagliptin + metforminc | 895 (72.8) | 720 (84.0) | 1615 (77.4) | <0.0001b | Vildagliptin/metformin FDCd | 299 (24.3) | 124 (14.5) | 423 (20.3) | | Pharmacotherapy at baseline, n (%) | Second-line therapy | 1181 (96.0) | 775 (90.4) | 1956 (93.7) | <0.0001b | Third- or further-line therapy | 43 (3.5) | 76 (8.9) | 119 (5.7) | | ∆HbA1c (%) | 12 weeks | | | | | N | 923 | 699 | 1622 | | Mean ± SD | −0.9 ± 1.1 | −0.6 ± 1.2 | −0.8 ± 1.2 | <0.0001b | 24 weeks | | | N | 1230 | 857 | 2087 | | Mean ± SD | −1.2 ± 1.2 | −0.8 ± 1.3 | −1.0 ± 1.3 | <0.0001b | ∆FBG (mg/dL) | 12 weeks | N | 535 | 359 | 894 | | Mean ± SD | −30.9 ± 47.1 | −24.2 ± 57.7 | −28.2 ± 51.7 | 0.0673b | 24 weeks | | | N | 663 | 406 | 1069 | | Mean ± SD | −32.6 ± 48.8 | −23.0 ± 60.2 | −29.0 ± 53.6 | 0.0068b |
|
|
SD: standard deviation; T2DM: type 2 diabetes mellitus; FDC: fixed drug combination; FBG: fasting blood glucose. aChi-square test. bt-test. cVildagliptin + metformin free drug combination. dVildagliptin/metformin fixed dose combination.
|